Potentials of interferon therapy in the treatment of pancreatic cancer

Journal of Interferon and Cytokine Research

Volumn 35, Issue 5, 2015, Pages 327-339

  Booy, Stephanie ^a   Hofland, Leo ^a   Van Eijck, Casper ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERFERON RECEPTOR; ANTINEOPLASTIC AGENT; INTERFERON;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE ARREST; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNOREGULATION; IN VITRO STUDY; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADJUVANT CHEMOTHERAPY; ANIMAL; GENETICS; METABOLISM; METASTASIS; PALLIATIVE THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; HUMANS; INTERFERONS; NEOPLASM METASTASIS; PALLIATIVE CARE; PANCREATIC NEOPLASMS; RECEPTORS, INTERFERON;

EID: 84928948847     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0157     Document Type: Article

References (106)

1. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Jr., Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Re-intgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. 2001. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19(16):3635-3648.
2. Bekisz J, Baron S, Balinsky C, Morrow A, Zoon KC. 2010. Antiproliferative properties of Type I and Type II interferon. Pharmaceuticals (Basel) 3(4):994-1015.
3. Bekisz J, Schmeisser H, Hernandez J, Goldman ND, Zoon KC. 2004. Human interferons alpha, beta and omega. Growth Factors 22(4):243-251.
4. Bernhard H, Jager-Arand E, Bernhard G, Heike M, Klein O, Riemann JF, Meyer zum Buschenfelde KH, Dippold W, Knuth A. 1995. Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial. Br J Cancer 71(1):102-105.
5. Booy S, Hofland LJ, Waaijers AM, Croze E, van Koetsveld PM, de Vogel L, Biermann K, van Eijck CH. 2014a. Type I interferon receptor expression in human pancreatic and peri-ampullary cancer tissue. Pancreas. [Epub ahead of print]; DOI: 10.1097/MPA.0000000000000202.
6. Booy S, van Eijck CHJ, Dogan F, van Koetsveld PM, Hofland LJ. 2014b. Influence of type-I Interferon receptor expression level on the response to type-I Interferons in human pancreatic cancer cells. J Cell Mol Med 18(3):492-502.
7. Bracarda S, Eggermont AM, Samuelsson J. 2010. Redefining the role of interferon in the treatment of malignant diseases. Eur J Cancer 46(2):284-297.
8. Bradley JD, Scott CB, Paris KJ, Demas WF, Machtay M, Ko-maki R, Movsas B, Rubin P, Sause WT. 2002. A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04). Int J Radiat Oncol Biol Phys 52(5):1173-1179.
9. Brembeck FH, Schoppmeyer K, Leupold U, Gornistu C, Keim V, Mossner J, Riecken EO, Rosewicz S. 1998. A phase II pilot trial of 13-cis retinoic acid and interferon-alpha in patients with advanced pancreatic carcinoma. Cancer 83(11):2317-2323.
10. Brunicardi FC, Fisher WE. 2007. Differences between ampul-lary, periampullary and pancreatic cancer (vol 31, pg 144, 2007). World J Surg 31(11):2274-2274.
11. Bruzzese F, Di Gennaro E, Avallone A, Pepe S, Arra C, Caraglia M, Tagliaferri P, Budillon A. 2006. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. Clin Cancer Res 12(2):617-625.
12. Buchwalder PA, Buclin T, Trinchard I, Munafo A, Biollaz J. 2000. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res 20(10): 857-866.
13. Caraglia M, Marra M, Tagliaferri P, Lamberts SW, Zappavigna S, Misso G, Cavagnini F, Facchini G, Abbruzzese A, Hofland LJ, Vitale G. 2009. Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. Curr Cancer Drug Targets 9(5):690-704.
14. Caraglia M, Marra M, Viscomi C, D'Alessandro AM, Budillon A, Meo G, Arra C, Barbieri A, Rapp UR, Baldi A, Tassone P, Venuta S, Abbruzzese A, Tagliaferri P. 2007. The farnesyl-transferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways. Int J Cancer 121(10):2317-2330.
15. Caraglia M, Vitale G, Marra M, Budillon A, Tagliaferri P, Ab-bruzzese A. 2004. Alpha-interferon and its effects on signalling pathways within cells. Curr Protein Pept Sci 5(6):475-485.
16. Chao MP, Weissman IL, Majeti R. 2012. The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol 24(2):225-232.
17. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC. 2003. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8(3):237-249.
18. Chofflon M. 2000. Recombinant human interferon beta in relapsing-remitting multiple sclerosis: a review of the major clinical trials. Eur J Neurol 7(4):369-380.
19. Chronic Myeloid Leukemia Trialists' Collaborative Group. 1997. Interferon alfa versus chemotherapy for chronic mye-loid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 89(21):1616-1620.
20. Clerico M, Contessa G, Durelli L. 2007. Interferon-beta1a for the treatment of multiple sclerosis. Expert Opin Biol Ther 7(4):535-542.
21. Colman H, Berkey BA, Maor MH, Groves MD, Schultz CJ, Vermeulen S, Nelson DF, Mehta MP, Yung WK; Radiation Therapy Oncology Group. 2006. Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for su-pratentorial glioblastoma: results of RTOG 9710. Int J Radiat Oncol Biol Phys 66(3):818-824.
22. Darnell JE, Jr., Kerr IM, Stark GR. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264(5164):1415-1421.
23. David AK, Vaughn DJ, Holroyde CP, Armstead B, Haller DG. 2000. A phase II trial of 5-fluorouracil, leucovorin, and interferon alpha 2A (IFN-alpha 2a) in metastatic pancreatic carcinoma: a Penn Cancer Clinical Trials Group (PCCTG) trial. Am J Clin Oncol 23(1):37-39.
24. de Weerd NA, Vivian JP, Nguyen TK, Mangan NE, Gould JA, Braniff SJ, Zaker-Tabrizi L, Fung KY, Forster SC, Beddoe T, Reid HH, Rossjohn J, Hertzog PJ. 2013. Structural basis of a unique interferon-beta signaling axis mediated via the receptor IFNAR1. Nat Immunol 14(9):901-907.
25. Dicitore A, Caraglia M, Gaudenzi G, Manfredi G, Amato B, Mari D, Persani L, Arra C, Vitale G. 2014. Type I interferonmediated pathway interacts with peroxisome proliferator activated receptor-gamma (PPAR-gamma): at the cross-road of pancreatic cancer cell proliferation. Biochim Biophys Acta 1845(1):42-52.
26. Domanski P, Colamonici OR. 1996. The type-I interferon receptor. The long and short of it. Cytokine Growth Factor Rev 7(2):143-151.
27. Dummer R, Hauschild A, Guggenheim M, Jost L, Penther-oudakis G, Group EGW. 2010. Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 (Suppl. 5):v194-v197.
28. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, Diamond MS, Koebel CM, Arthur C, White JM, Schreiber RD. 2005. A critical function for type I interferons in cancer immunoediting. Nat Immunol 6(7):722-729.
29. Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, Punt CJ, Sales F, Dummer R, Robert C, Schadendorf D, Patel PM, de Schaetzen G, Spatz A, Keilholz U. 2012. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 30(31):3810-3818.
30. Fazio N, de Braud F, Delle Fave G, Oberg K. 2007. Interferonalpha and somatostatin analog in patients with gastro-enteropancreatic neuroendocrine carcinoma: single agent or combination? Ann Oncol 18(1):13-19.
31. Fellous M, Nir U, Wallach D, Merlin G, Rubinstein M, Revel M. 1982. Interferon-dependent induction of mRNA for the major histocompatibility antigens in human fibroblasts and lympho-blastoid cells. Proc Natl Acad Sci U S A 79(10):3082-3086.
32. Foster GR, Finter NB. 1998. Are all type I human interferons equivalent? J Viral Hepat 5(3):143-152.
33. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, Grob JJ, Malvehy J, Newton-Bishop J, Stratigos A, Pe-hamberger H, Eggermont AM, European Dermatology F, European Association of D-O, European Organization of R, Treatment of C. 2012. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline- Update 2012. Eur J Cancer 48(15):2375-2390.
34. Hakansson A, Gustafsson B, Krysander L, Hakansson L. 1996. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer 74(5):670-676.
35. Hayashi T, Ding Q, Kuwahata T, Maeda K, Miyazaki Y, Mat-subara S, Obara T, Natsugoe S, Takao S. 2012. Interferon-alpha modulates the chemosensitivity of CD133-expressing pancreatic cancer cells to gemcitabine. Cancer Sci 103(5):889-896.
36. Hoffmann K, Mehrle S, Schmidt J, Buchler MW, Marten A. 2008. Interferon-alpha restitutes the chemosensitivity in pancreatic cancer. Anticancer Res 28(3A):1499-1507.
37. Hu X, Miller L, Richman S, Hitchman S, Glick G, Liu S, Zhu Y, Crossman M, Nestorov I, Gronke RS, Baker DP, Rogge M, Subramanyam M, Davar G. 2012. A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. J Clin Pharmacol 52(6):798-808.
38. Isaacs A, Lindenmann J. 1957. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147(927):258-267.
39. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin 61(2):69-90.
40. John WJ, Flett MQ. 1998. Continuous venous infusion 5-fluorouracil and interferon-alpha in pancreatic carcinoma. Am J Clin Oncol 21(2):147-150.
41. Jost E, Roos WP, Kaina B, Schmidberger H. 2010. Response of pancreatic cancer cells treated with interferon-alpha or beta and co-exposed to ionising radiation. Int J Radiat Biol 86(9): 732-741.
42. Katz MH, Wolff R, Crane CH, Varadhachary G, Javle M, Lin E, Evans DB, Lee JE, Fleming JB, Pisters PW. 2011. Survival and quality of life of patients with resected pancreatic ade-nocarcinoma treated with adjuvant interferon-based chemor-adiation: a phase II trial. Ann Surg Oncol 18(13):3615-3622.
43. Khallouf H, Marten A, Serba S, Teichgraber V, Buchler MW, Jager D, Schmidt J. 2012. 5-Fluorouracil and interferon-alpha immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I. J Immunother 35(3):245-253.
44. Kirkwood JM, Harris JE, Vera R, Sandler S, Fischer DS, Khandekar J, Ernstoff MS, Gordon L, Lutes R, Bonomi P, et al. 1985. A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res 45(2):863-871.
45. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH. 2000. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18(12):2444-2458.
46. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. 2005. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 23(3):202-212.
47. Lindner DJ, Borden EC. 1997. Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogene-sis. Int J Cancer 71(3):456-461.
48. Linehan DC, Tan MC, Strasberg SM, Drebin JA, Hawkins WG, Picus J, Myerson RJ, Malyapa RS, Hull M, Trinkaus K, Tan BR, Jr. 2008. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study. Ann Surg 248(2):145-151.
49. Ma JH, Patrut E, Schmidt J, Knaebel HP, Buchler MW, Marten A. 2005. Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarci-noma. World J Gastroenterol 11(10):1521-1528.
50. Macdonald JS, Jacobson JL, Modiano M, Moore DF, Gandara DR, Schroder LE, Chapman RA. 2000. A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) +G-CSF for patients with pancreatic adenocarcinoma: a Southwest Oncology Group study (SWOG 9413). Invest New Drugs 18(3):269-273.
51. Mager DE, Neuteboom B, Jusko WJ. 2005. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys. Pharm Res 22(1): 58-61.
52. Matsubara N, Fuchimoto S, Orita K. 1991. Antiproliferative effects of natural human tumor necrosis factor-alpha, interferonalpha, and interferon-gamma on human pancreatic carcinoma cell lines. Int J Pancreatol 8(3):235-243.
53. Medical Research Council Renal Cancer Collaborators. 1999. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353(9146): 14-17.
54. Mitsuyasu RT. 1991. Interferon alpha in the treatment of AIDS-related Kaposi's sarcoma. Br J Haematol 79 (Suppl. 1):69-73.
55. Miyake K, Tsuchida K, Sugino H, Imura S, Morine Y, Fujii M, Shimada M. 2007. Combination therapy of human pancreatic cancer implanted in nude mice by oral fluoropyrimidine anticancer agent (S-1) with interferon-alpha. Cancer Chemother Pharmacol 59(1):113-126.
56. Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V. 2013. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev 6:CD008955.
57. Moore DF, Jr., Pazdur R, Sugarman S, Jones D, 3rd, Lippman SM, Bready B, Abbruzzese JL. 1995. Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha combination therapy for advanced pancreatic adenocarcinoma. Am J Clin Oncol 18(6):525-527.
58. Moore MJ, Erlichman C, Kaizer L, Fine S. 1993. A phase II study of 5-fluorouracil, leucovorin and interferon-alpha in advanced pancreatic cancer. Anticancer Drugs 4(5):555-557.
59. Morak MJ, van Koetsveld PM, Kanaar R, Hofland LJ, van Eijck CH. 2011. Type I interferons as radiosensitisers for pancreatic cancer. Eur J Cancer 47(13):1938-1945.
60. Motzer RJ, Rakhit A, Thompson J, Gurney H, Selby P, Figlin R, Negrier S, Ernst S, Siebels M, Ginsberg M, Rittweger K, Hooftman L. 2002. Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma. Ann Oncol 13(11):1799-1805.
61. NA. 2014. Blocking CD47 shrinks pancreatic tumors. Cancer Discov 4(8):864.
62. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T. 1998. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 338(18):1272-1278.
63. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Buchler MW; European Study Group for Pancreatic C. 2004. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350(12): 1200-1210.
64. Nitsche M, Horstmann O, Christiansen H, Hermann RM, Hess CF, Becker H, Pradier O, Schmidberger H. 2008. Chemor-adioimmunotherapy with 5-fluorouracil, cisplatin and interferonalpha in pancreatic and periampullary cancer: results of a feasibility study. Cancer Radiother 12(8):817-821.
65. Novick D, Cohen B, Rubinstein M. 1994. The human interferon alpha/beta receptor: characterization and molecular cloning. Cell 77(3):391-400.
66. Nukui Y, Picozzi VJ, Traverso LW. 2000. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 179(5):367-371.
67. Odaka M, Sterman DH, Wiewrodt R, Zhang Y, Kiefer M, Amin KM, Gao GP, Wilson JM, Barsoum J, Kaiser LR, Albelda SM. 2001. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity. Cancer Res 61(16): 6201-6212.
68. Pazdur R, Ajani JJ, Abbruzzese JL, Belt RJ, Dakhil SR, Du-bovsky D, Graham S, Pilat S, Winn R, Levin B. 1992. Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer 70(8):2073-2076.
69. Pestka S, Langer JA, Zoon KC, Samuel CE. 1987. Interferons and their actions. Annu Rev Biochem 56:727-777.
70. Picozzi VJ, Abrams RA, Decker PA, Traverso W, O'Reilly EM, Greeno E, Martin RC, Wilfong LS, Rothenberg ML, Posner MC, Pisters PW; American College of Surgeons Oncology G. 2011. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol 22(2):348-354.
71. Picozzi VJ, Kozarek RA, Traverso LW. 2003. Interferon-based adjuvant chemoradiation therapy after pancreaticoduode-nectomy for pancreatic adenocarcinoma. Am J Surg 185(5): 476-480.
72. Quesada JR, Alexanian R, Hawkins M, Barlogie B, Borden E, Itri L, Gutterman JU. 1986. Treatment of multiple myeloma with recombinant alpha-interferon. Blood 67(2):275-278.
73. Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU. 1984. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 310(1):15-18.
74. Raig ET, Jones NB, Varker KA, Benniger K, Go MR, Biber JL, Lesinski GB, Carson WE, 3rd. 2008. VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines. J Interferon Cytokine Res 28(9):553-561.
75. Recchia F, Sica G, Candeloro G, Necozione S, Bisegna R, Bratta M, Rea S. 2009. Beta-interferon, retinoids and ta-moxifen in metastatic breast cancer: long-term follow-up of a phase II study. Oncol Rep 21(4):1011-1016.
76. Recchia F, Sica G, Casucci D, Rea S, Gulino A, Frati L. 1998. Advanced carcinoma of the pancreas: phase II study of combined chemotherapy, beta-interferon, and retinoids. Am J Clin Oncol 21(3):275-278.
77. Repetto L, Giannessi PG, Campora E, Pronzato P, Vigani A, Naso C, Spinelli I, Conte PF, Rosso R. 1996. Tamoxifen and interferon-beta for the treatment of metastatic breast cancer. Breast Cancer Res Treat 39(2):235-238.
78. Roos G, Leanderson T, Lundgren E. 1984. Interferon-induced cell cycle changes in human hematopoietic cell lines and fresh leukemic cells. Cancer Res 44(6):2358-2362.
79. Rosewicz S, Weder M, Kaiser A, Riecken EO. 1996. Anti-proliferative effects of interferon alpha on human pancreatic carcinoma cell lines are associated with differential regulation of protein kinase C isoenzymes. Gut 39(2):255-261.
80. Rubinstein M, Levy WP, Moschera JA, Lai CY, Hershberg RD, Bartlett RT, Pestka S. 1981. Human leukocyte interferon: isolation and characterization of several molecular forms. Arch Biochem Biophys 210(1):307-318.
81. Rudick RA, Goelz SE. 2011. Beta-interferon for multiple sclerosis. Exp Cell Res 317(9):1301-1311.
82. Saidi RF, Ahad A, Tilak J, Nalbantoglu I, Jacobs MJ. 2012. The expression of interferon receptor alpha/beta in human pancreatic cancer in nude mice is essential for tumor response to interferon alpha treatment. J Surg Res 173(2):309-313.
83. Saidi RF, Remine SG, Jacobs MJ. 2007. Interferon receptor alpha/beta is associated with improved survival after adjuvant therapy in resected pancreatic cancer. HPB (Oxford) 9(4): 289-294.
84. Saidi RF, Williams F, Ng J, Danquah G, Mittal VK, ReMine SG, Jacobs MJ. 2006a. Interferon receptors and the caspase cascade regulate the antitumor effects of interferons on human pancreatic cancer cell lines. Am J Surg 191(3):358-363.
85. Saidi RF, Williams F, Silberberg B, Mittal VK, ReMine SG, Jacobs MJ. 2006b. Expression of interferon receptors in pancreatic cancer: identification of a novel prognostic factor. Surgery 139(6):743-748.
86. Sandoval R, Xue J, Pilkinton M, Salvi D, Kiyokawa H, Cola-monici OR. 2004. Different requirements for the cytostatic and apoptotic effects of type I interferons. Induction of ap-optosis requires ARF but not p53 in osteosarcoma cell lines. J Biol Chem 279(31):32275-32280.
87. Sangfelt O, Erickson S, Castro J, Heiden T, Gustafsson A, Einhorn S, Grander D. 1999. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene 18(18):2798-2810.
88. Scheithauer W, Pfeffel F, Kornek G, Marczell A, Wiltschke C, Funovics J. 1992. A phase II trial of 5-fluorouracil, leucov-orin, and recombinant alpha-2b-interferon in advanced ade-nocarcinoma of the pancreas. Cancer 70(7):1864-1866.
89. Schmidt J, Abel U, Debus J, Harig S, Hoffmann K, Herrmann T, Bartsch D, Klein J, Mansmann U, Jager D, Capussotti L, Kunz R, Buchler MW. 2012. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol 30(33):4077-4083.
90. Schmidt J, Patrut EM, Ma J, Jager D, Knaebel HP, Buchler MW, Marten A. 2006. Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI). Cancer Immunol Immunother 55(11):1396-1405.
91. Sideras K, Braat H, Kwekkeboom J, van Eijck CH, Peppe-lenbosch MP, Sleijfer S, Bruno M. 2014. Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treat Rev 40(4): 513-522.
92. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. 1995. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A 92(10):4562-4566.
93. Solorzano CC, Hwang R, Baker CH, Bucana CD, Pisters PW, Evans DB, Killion JJ, Fidler IJ. 2003. Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice. Clin Cancer Res 9(5):1858-1867.
94. Sparano JA, Lipsitz S, Wadler S, Hansen R, Bushunow PW, Kirkwood J, Flynn PJ, Dutcher JP, Benson AB. 1996. Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292. Am J Clin Oncol 19(6):546-551.
95. Sporn JR, Buzaid AC, Slater D, Cohen N, Greenberg BR. 1997. Treatment of advanced pancreatic adenocarcinoma with 5-FU, leucovorin, interferon-alpha-2b, and cisplatin. Am J Clin Oncol 20(1):81-83.
96. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. 1998. How cells respond to interferons. Annu Rev Biochem 67:227-264.
97. Sterman DH, Recio A, Haas AR, Vachani A, Katz SI, Gillespie CT, Cheng G, Sun J, Moon E, Pereira L, Wang X, Heitjan DF, Litzky L, June CH, Vonderheide RH, Carroll RG, Albelda SM. 2010. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther 18(4):852-860.
98. Tomimaru Y, Eguchi H, Wada H, Tomokuni A, Kobayashi S, Marubashi S, Takeda Y, Tanemura M, Umeshita K, Mori M, Doki Y, Nagano H. 2011. Synergistic antitumor effect of interferon-ss with gemcitabine in interferon-alpha-non-responsive pancreatic cancer cells. Int J Oncol 38(5):1237-1243.
99. Verbeke CS, Gladhaug IP. 2012. Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg 99(8):1036-1049.
100. Vitale G, van Eijck CH, van Koetsveld Ing PM, Erdmann JI, Speel EJ, van der Wansem Ing K, Mooij DM, Colao A, Lombardi G, Croze E, Lamberts SW, Hofland LJ. 2007. Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Ann Surg 246(2):259-268.
101. Vitale G, Zappavigna S, Marra M, Dicitore A, Meschini S, Condello M, Arancia G, Castiglioni S, Maroni P, Bendinelli P, Piccoletti R, van Koetsveld PM, Cavagnini F, Budillon A, Abbruzzese A, Hofland LJ, Caraglia M. 2012. The PPAR-gamma agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-beta treated pancreatic cancer cells. Biotechnol Adv 30(1):169-184.
102. von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, Wiedenmann B, Hocker M, Rosewicz S. 2003. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 95(6):437-448.
103. Wagener DJ, Wils JA, Kok TC, Planting A, Couvreur ML, Baron B. 2002. Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluoro-uracil with alpha-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial. Eur J Cancer 38(5):648-653.
104. Wagner TC, Velichko S, Chesney SK, Biroc S, Harde D, Vogel D, Croze E. 2004. Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors. Int J Cancer 111(1):32-42.
105. Zhu Y, Tibensky I, Schmidt J, Hackert T, Ryschich E, Jager D, Buchler MW, Marten A. 2008a. Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma. J Immunother 31(1):28-33.
106. Zhu Y, Tibensky I, Schmidt J, Ryschich E, Marten A. 2008b. Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma. J Immunother 31(7):599-606.